{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:24:15Z","timestamp":1790767455289,"version":"4.1.0"},"reference-count":123,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:p>Interest in nanomedicines has grown rapidly over the past two decades, owing to the promising therapeutic applications they may provide, particularly for the treatment of cancer. Personalised medicine and \u2018smart\u2019 actively targeted nanoparticles represent an opportunity to deliver therapies directly to cancer cells and provide sustained drug release, in turn providing overall lower off-target toxicity and increased therapeutic efficacy. However, the successful translation of nanomedicines from encouraging pre-clinical findings to the clinic has, to date, proven arduous. In this review, we will discuss the use of nanomedicines for the treatment of cancer, with a specific focus on the use of polymeric and lipid nanoparticle delivery systems. In particular, we examine approaches exploring the surface functionalisation of nanomedicines to elicit active targeting and therapeutic effects as well as challenges and future directions for nanoparticles in cancer treatment.<\/jats:p>","DOI":"10.1042\/bst20210343","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T13:44:28Z","timestamp":1635428668000},"page":"2253-2269","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface"],"prefix":"10.1042","volume":"49","author":[{"given":"Shannon R.","family":"Tracey","sequence":"first","affiliation":[{"name":"The Patrick G Johnston Centre for Cancer Research, Queen's University, 97 Lisburn Road, Belfast BT9 7AE, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Smyth","sequence":"additional","affiliation":[{"name":"The Patrick G Johnston Centre for Cancer Research, Queen's University, 97 Lisburn Road, Belfast BT9 7AE, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"Barelle","sequence":"additional","affiliation":[{"name":"Elasmogen Ltd, Liberty Building, Foresterhill Health Campus, Aberdeen AB25 2ZP, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7582-3808","authenticated-orcid":false,"given":"Christopher J.","family":"Scott","sequence":"additional","affiliation":[{"name":"The Patrick G Johnston Centre for Cancer Research, Queen's University, 97 Lisburn Road, Belfast BT9 7AE, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"2021111916153567000_BST-2021-0343CC1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021111916153567000_BST-2021-0343CC2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/IJN.S596","article-title":"Drug delivery and nanoparticles:applications and hazards","volume":"3","year":"2008","journal-title":"Int. J. Nanomedicine"},{"key":"2021111916153567000_BST-2021-0343CC3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1039\/c3ib40165k","article-title":"Nanoparticles and their applications in cell","volume":"6","year":"2011","journal-title":"Anal. Chem."},{"key":"2021111916153567000_BST-2021-0343CC4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.addr.2011.02.001","article-title":"Physical and chemical stability of drug nanoparticles","volume":"63","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021111916153567000_BST-2021-0343CC5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jconrel.2016.07.028","article-title":"Accumulating nanoparticles by EPR: a route of no return","volume":"238","year":"2016","journal-title":"J. Control Release"},{"key":"2021111916153567000_BST-2021-0343CC6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021111916153567000_BST-2021-0343CC7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in development of nanoparticle-based therapeutics","volume":"14","year":"2012","journal-title":"AAPS J."},{"key":"2021111916153567000_BST-2021-0343CC8","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: entering the mainstream","volume":"303","year":"2004","journal-title":"Science"},{"key":"2021111916153567000_BST-2021-0343CC9","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.2174\/1389450119666180326122831","article-title":"Nanoparticles in cancer treatment: opportunities and obstacles","volume":"19","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"2021111916153567000_BST-2021-0343CC10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/btm2.10100","article-title":"Nanoparticles in the clinic: an update","volume":"4","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"2021111916153567000_BST-2021-0343CC11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","year":"2010","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"2021111916153567000_BST-2021-0343CC12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.msec.2015.11.067","article-title":"Polymeric nanoparticles for targeted drug delivery system for cancer therapy","volume":"60","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"2021111916153567000_BST-2021-0343CC13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/btm2.10003","article-title":"Nanoparticles in the clinic","volume":"1","year":"2016","journal-title":"Bioeng. Transl. Med."},{"key":"2021111916153567000_BST-2021-0343CC14","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1021\/bc800057g","article-title":"Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells","volume":"19","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"2021111916153567000_BST-2021-0343CC15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40169-017-0175-0","article-title":"Cancer nanomedicine: a review of recent success in drug delivery","volume":"6","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"2021111916153567000_BST-2021-0343CC16","doi-asserted-by":"publisher","first-page":"E466","DOI":"10.1208\/aapsj080355","article-title":"Issues related to targeted delivery of proteins and peptides","volume":"8","year":"2006","journal-title":"AAPS J."},{"key":"2021111916153567000_BST-2021-0343CC17","first-page":"595","article-title":"Lipid-based colloidal carriers for peptide and protein delivery: liposomes versus lipid nanoparticles","volume":"2","year":"2007","journal-title":"Int. J. Nanomedicine"},{"key":"2021111916153567000_BST-2021-0343CC18","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1039\/C9NA00308H","article-title":"Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers","volume":"1","year":"2019","journal-title":"Nanoscale Adv."},{"key":"2021111916153567000_BST-2021-0343CC19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-019-0490-2","article-title":"Investigation of PLGA nanoparticles in conjunction with nuclear localization sequence for enhanced delivery of antimiR phosphorothioates in cancer cells in vitro","volume":"17","year":"2019","journal-title":"J. Nanobiotechnology"},{"key":"2021111916153567000_BST-2021-0343CC20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae: the first FDA-approved nano-drug: lessons learned","volume":"160","year":"2012","journal-title":"J. Control Release"},{"key":"2021111916153567000_BST-2021-0343CC21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13020206","article-title":"Lipid nanoparticles as delivery systems for RNA-based vaccines","volume":"13","year":"2021","journal-title":"Pharmaceutics"},{"key":"2021111916153567000_BST-2021-0343CC22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4155\/tde-2020-0123","article-title":"Folic acid decorated chitosan-coated solid lipid nanoparticles for the oral treatment of rheumatoid arthritis","volume":"12","year":"2021","journal-title":"Ther. Deliv."},{"key":"2021111916153567000_BST-2021-0343CC23","doi-asserted-by":"publisher","first-page":"101142","DOI":"10.1016\/j.nantod.2021.101142","article-title":"Role of nanotechnology behind the success of mRNA vaccines for COVID-19","volume":"38","year":"2021","journal-title":"Nano Today"},{"key":"2021111916153567000_BST-2021-0343CC24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41565-021-00901-8","article-title":"COVID-19 may become nanomedicines finest hour yet","volume":"16","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"2021111916153567000_BST-2021-0343CC25","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00611-y","article-title":"FDA's regulatory science program for generic PLA\/PLGA-based drug products","volume":"20","year":"2016","journal-title":"Am. Pharm. Rev."},{"key":"2021111916153567000_BST-2021-0343CC26","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","year":"2016","journal-title":"Pharm. Res."},{"key":"2021111916153567000_BST-2021-0343CC27","first-page":"3752","article-title":"Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size1","volume":"55","year":"1995","journal-title":"Cancer Res."},{"key":"2021111916153567000_BST-2021-0343CC28","first-page":"283","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"2021111916153567000_BST-2021-0343CC29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting","volume":"41","year":"2001","journal-title":"Adv. Enzyme Regul."},{"key":"2021111916153567000_BST-2021-0343CC30","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","year":"1986","journal-title":"Cancer Res."},{"key":"2021111916153567000_BST-2021-0343CC31","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/jphp.13098","article-title":"An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites","volume":"71","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"2021111916153567000_BST-2021-0343CC32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","article-title":"Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity","volume":"91","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021111916153567000_BST-2021-0343CC33","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","article-title":"Challenges and key considerations of the enhanced permeability and retention (EPR) effect for nanomedicine drug delivery in oncology","volume":"73","year":"2013","journal-title":"Cancer Res."},{"key":"2021111916153567000_BST-2021-0343CC34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: strategies to enhance patient responses","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021111916153567000_BST-2021-0343CC35","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"2021111916153567000_BST-2021-0343CC36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/jpm11030229","article-title":"The 35th anniversary of the discovery of EPR effect: a new wave of nanomedicines for tumor-targeted drug delivery-personal remarks and future prospects","volume":"11","year":"2021","journal-title":"J. Pers. Med."},{"key":"2021111916153567000_BST-2021-0343CC37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/pharmaceutics11070343","article-title":"Augmentation of epr effect and efficacy of anticancer nanomedicine by carbon monoxide generating agents","volume":"11","year":"2019","journal-title":"Pharmaceutics"},{"key":"2021111916153567000_BST-2021-0343CC38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2012.04.038","article-title":"Macromolecular therapeutics in cancer treatment: the EPR effect and beyond","volume":"164","year":"2012","journal-title":"J. Control Release"},{"key":"2021111916153567000_BST-2021-0343CC39","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1039\/C9TB02957E","article-title":"Anti-vascular nano agents: a promising approach for cancer treatment","volume":"8","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"2021111916153567000_BST-2021-0343CC40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","article-title":"Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers","volume":"157","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021111916153567000_BST-2021-0343CC41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"2021111916153567000_BST-2021-0343CC42","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"2021111916153567000_BST-2021-0343CC43","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","article-title":"Recent advances of antibody drug conjugates for clinical applications","volume":"10","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"2021111916153567000_BST-2021-0343CC44","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/ijms21155510","article-title":"Antibody-drug conjugates: the new frontier of chemotherapy","volume":"21","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2021111916153567000_BST-2021-0343CC45","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1021\/acsmedchemlett.9b00301","article-title":"Synthesis and evaluation of camptothecin antibody-drug conjugates","volume":"10","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"2021111916153567000_BST-2021-0343CC46","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"Geruxtecan-Nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2021111916153567000_BST-2021-0343CC47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody\u2013drug conjugates in solid tumors: a look into novel targets","volume":"14","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"2021111916153567000_BST-2021-0343CC48","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1358\/dot.2019.55.9.3039669","article-title":"Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors","volume":"55","year":"2019","journal-title":"Drugs Today"},{"key":"2021111916153567000_BST-2021-0343CC49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ddtec.2018.10.003","article-title":"Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy","volume":"30","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"2021111916153567000_BST-2021-0343CC50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2147\/IJN.S36654","article-title":"Targeted therapy using nanotechnology: focus on cancer","volume":"9","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"2021111916153567000_BST-2021-0343CC51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021111916153567000_BST-2021-0343CC52","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3892\/mco.2014.356","article-title":"Passive targeting of nanoparticles to cancer: a comprehensive review of the literature","volume":"2","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"2021111916153567000_BST-2021-0343CC53","doi-asserted-by":"publisher","first-page":"10327","DOI":"10.1039\/C7NR03042H","article-title":"Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells","volume":"9","year":"2017","journal-title":"Nanoscale"},{"key":"2021111916153567000_BST-2021-0343CC54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.021","article-title":"Nanoparticles-a historical perspective","volume":"331","year":"2007","journal-title":"Int. J. Pharm."},{"key":"2021111916153567000_BST-2021-0343CC55","doi-asserted-by":"publisher","first-page":"e1454","DOI":"10.1038\/cddis.2014.413","article-title":"Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity","volume":"5","year":"2014","journal-title":"Cell Death Dis."},{"key":"2021111916153567000_BST-2021-0343CC56","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"2021111916153567000_BST-2021-0343CC57","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4155\/bio.10.204","article-title":"In vitro and in vivo characterizations of PEGylated liposomal doxorubicin","volume":"3","year":"2011","journal-title":"Bioanalysis"},{"key":"2021111916153567000_BST-2021-0343CC58","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1039\/C5NR09158F","article-title":"Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles","volume":"8","year":"2016","journal-title":"Nanoscale"},{"key":"2021111916153567000_BST-2021-0343CC59","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s40265-020-01336-6","article-title":"Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma","volume":"80","year":"2020","journal-title":"Drugs"},{"key":"2021111916153567000_BST-2021-0343CC60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4143\/crt.2016.376","article-title":"An open-label, randomized, parallel, phase ii trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: a Korean gynecologic oncology group study (KGOG-3021)","volume":"50","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"2021111916153567000_BST-2021-0343CC61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10549-007-9591-y","article-title":"Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer","volume":"108","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"2021111916153567000_BST-2021-0343CC62","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.2174\/13816128113199990375","article-title":"The smart targeting of nanoparticles","volume":"19","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"2021111916153567000_BST-2021-0343CC63","doi-asserted-by":"publisher","first-page":"7671","DOI":"10.1039\/C9CC02655J","article-title":"Oriented attachment of VNAR proteins: via site-selective modification, on PLGA-PEG nanoparticles enhances nanoconjugate performance","volume":"55","year":"2019","journal-title":"Chem. Commun."},{"key":"2021111916153567000_BST-2021-0343CC64","doi-asserted-by":"publisher","first-page":"14751","DOI":"10.1039\/D0NR02962A","article-title":"Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature","volume":"12","year":"2020","journal-title":"Nanoscale"},{"key":"2021111916153567000_BST-2021-0343CC65","doi-asserted-by":"publisher","first-page":"11647","DOI":"10.1039\/D0NR02387F","article-title":"Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cells","volume":"12","year":"2020","journal-title":"Nanoscale"},{"key":"2021111916153567000_BST-2021-0343CC66","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jconrel.2020.05.046","article-title":"DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models","volume":"324","year":"2020","journal-title":"J. Control Release"},{"key":"2021111916153567000_BST-2021-0343CC67","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1042\/BST20180177","article-title":"Next-generation flexible formats of VNAR domains expand the drug platform's utility and developability","volume":"46","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"2021111916153567000_BST-2021-0343CC68","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1517\/14712598.2014.937701","article-title":"Shark variable new antigen receptor biologics: a novel technology platform for therapeutic drug development","volume":"14","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"2021111916153567000_BST-2021-0343CC69","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3390\/ijms20092088","article-title":"Single-domain antibodies represent novel alternatives to monoclonal antibodies as targeting agents against the human papillomavirus 16 E6 protein","volume":"20","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"2021111916153567000_BST-2021-0343CC70","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jconrel.2018.03.002","article-title":"Insights into maleimide-thiol conjugation chemistry: conditions for efficient surface functionalization of nanoparticles for receptor targeting","volume":"282","year":"2018","journal-title":"J. Control Release"},{"key":"2021111916153567000_BST-2021-0343CC71","first-page":"221","article-title":"Comparative analysis of nanoparticle-antibody conjugations: carbodiimide versus click chemistry","volume":"8","year":"2009","journal-title":"Mol. Imaging"},{"key":"2021111916153567000_BST-2021-0343CC72","doi-asserted-by":"publisher","first-page":"12006","DOI":"10.1002\/ange.201206703","article-title":"Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles","volume":"124","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2021111916153567000_BST-2021-0343CC73","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","article-title":"Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial","volume":"4","year":"2018","journal-title":"JAMA Oncol."},{"key":"2021111916153567000_BST-2021-0343CC74","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1200\/jco.2016.34.2_suppl.233","article-title":"A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer (mCRPC)","volume":"34","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2021111916153567000_BST-2021-0343CC75","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1021\/bc050137k","article-title":"Biodegradable nanoparticles for direct or two-step tumor immunotargeting","volume":"17","year":"2006","journal-title":"Bioconjug Chem."},{"key":"2021111916153567000_BST-2021-0343CC76","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1039\/C7SC02747H","article-title":"Generating next-generation antibody-nanoparticle conjugates through the oriented installation of non-engineered antibody fragments","volume":"9","year":"2017","journal-title":"Chem. Sci"},{"key":"2021111916153567000_BST-2021-0343CC77","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jconrel.2015.04.026","article-title":"In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer","volume":"209","year":"2015","journal-title":"J. Control Release"},{"key":"2021111916153567000_BST-2021-0343CC78","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3389\/fimmu.2019.00526","article-title":"An anti-hTNF-\u03b1 variable new antigen receptor format demonstrates superior in vivo preclinical efficacy to humira\u00ae in a transgenic mouse autoimmune polyarthritis disease model","volume":"10","year":"2019","journal-title":"Front. Immunol."},{"key":"2021111916153567000_BST-2021-0343CC79","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.7150\/thno.11711","article-title":"Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors","volume":"5","year":"2015","journal-title":"Theranostics"},{"key":"2021111916153567000_BST-2021-0343CC80","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3390\/ijms21072485","article-title":"Antibodies, nanobodies, or aptamers\u2014which is best for deciphering the proteomes of non-model species?","volume":"21","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2021111916153567000_BST-2021-0343CC81","doi-asserted-by":"publisher","first-page":"9123","DOI":"10.3390\/ijms21239123","article-title":"Aptamer-functionalized nanoparticles in targeted delivery and cancer therapy","volume":"21","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2021111916153567000_BST-2021-0343CC82","doi-asserted-by":"publisher","first-page":"6239","DOI":"10.2147\/IJN.S143293","article-title":"EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer","volume":"12","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"2021111916153567000_BST-2021-0343CC83","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/1538-7445.AM2019-222","article-title":"Abstract 222: novel protein drug conjugates targeting ROR1 through the development and exploitation of a drug discovery platform based on small, engineered VNAR domains","volume":"79","year":"2019","journal-title":"Cancer Res."},{"key":"2021111916153567000_BST-2021-0343CC84","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib6040016","article-title":"Antibodies and derivatives targeting DR4 and DR5 for cancer therapy","volume":"6","year":"2017","journal-title":"Antibodies"},{"key":"2021111916153567000_BST-2021-0343CC85","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1002\/anie.201511894","article-title":"An apoptosis-inducing peptidic heptad that efficiently clusters death receptor 5","volume":"55","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2021111916153567000_BST-2021-0343CC86","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","year":"1999","journal-title":"Nat. Med."},{"key":"2021111916153567000_BST-2021-0343CC87","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"2021111916153567000_BST-2021-0343CC88","doi-asserted-by":"publisher","first-page":"8645","DOI":"10.1016\/j.biomaterials.2011.07.065","article-title":"Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery","volume":"32","year":"2011","journal-title":"Biomaterials"},{"key":"2021111916153567000_BST-2021-0343CC89","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/mt.2014.137","article-title":"Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine","volume":"22","year":"2014","journal-title":"Mol. Ther."},{"key":"2021111916153567000_BST-2021-0343CC90","doi-asserted-by":"publisher","first-page":"686108","DOI":"10.1155\/2012\/686108","article-title":"Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment","volume":"2012","year":"2012","journal-title":"J. Drug Deliv."},{"key":"2021111916153567000_BST-2021-0343CC91","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.addr.2019.04.008","article-title":"Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine","volume":"143","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021111916153567000_BST-2021-0343CC92","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1517\/17425247.2010.485983","article-title":"Cationic nanoparticles for cancer therapy","volume":"7","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"2021111916153567000_BST-2021-0343CC93","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1021\/acs.molpharmaceut.7b00997","article-title":"Cationic polymeric nanoparticle delivering CCR2 siRNA to inflammatory monocytes for tumor microenvironment modification and cancer therapy","volume":"15","year":"2018","journal-title":"Mol. Pharm."},{"key":"2021111916153567000_BST-2021-0343CC94","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1021\/nl101140t","article-title":"Effect of nanoparticle surface charge at the plasma membrane and beyond","volume":"10","year":"2010","journal-title":"Nano Lett."},{"key":"2021111916153567000_BST-2021-0343CC95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12989-016-0129-5","article-title":"Extracellular cathepsin S and intracellular caspase 1 activation are surrogate biomarkers of particulate-induced lysosomal disruption in macrophages","volume":"13","year":"2016","journal-title":"Part Fibre Toxicol."},{"key":"2021111916153567000_BST-2021-0343CC96","doi-asserted-by":"publisher","first-page":"742895","DOI":"10.1155\/2011\/742895","article-title":"Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy","volume":"2011","year":"2011","journal-title":"J. Nanomater."},{"key":"2021111916153567000_BST-2021-0343CC97","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1039\/C1CC10721F","article-title":"Cationic supramolecular nanoparticles for co-delivery of gene and anticancer drug","volume":"47","year":"2011","journal-title":"Chem. Commun."},{"key":"2021111916153567000_BST-2021-0343CC98","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1080\/21691401.2017.1395344","article-title":"Significant role of cationic polymers in drug delivery systems","volume":"46","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"2021111916153567000_BST-2021-0343CC99","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1007\/s10118-017-1982-x","article-title":"pH-responsive polymersome based on PMCP-b-PDPA as a drug delivery system to enhance cellular internalization and intracellular drug release","volume":"35","year":"2017","journal-title":"Chinese J. Polym. Sci."},{"key":"2021111916153567000_BST-2021-0343CC100","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1021\/ma302228m","article-title":"Effect of pH and temperature on PMPC\u2013PDPA copolymer self-assembly","volume":"46","year":"2013","journal-title":"Macromolecules"},{"key":"2021111916153567000_BST-2021-0343CC101","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1021\/acsmacrolett.8b00461","article-title":"Single-domain antibody-functionalized pH-responsive amphiphilic block copolymer nanoparticles for epidermal growth factor receptor targeted cancer therapy","volume":"7","year":"2018","journal-title":"ACS Macro Lett."},{"key":"2021111916153567000_BST-2021-0343CC102","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1021\/acs.bioconjchem.8b00778","article-title":"Overcoming endosomal entrapment in drug delivery","volume":"30","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"2021111916153567000_BST-2021-0343CC103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/marc.201800917","article-title":"pH-responsive polymer nanoparticles for drug delivery","volume":"40","year":"2019","journal-title":"Macromol. Rapid Commun."},{"key":"2021111916153567000_BST-2021-0343CC104","doi-asserted-by":"publisher","first-page":"7879","DOI":"10.1039\/D1NR01190A","article-title":"Multi-stimuli-responsive aggregation of nanoparticles driven by the manipulation of colloidal stability","year":"2021","journal-title":"Nanoscale"},{"key":"2021111916153567000_BST-2021-0343CC105","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0169-409X(01)00204-6","article-title":"Thermosensitive polymer-modified liposomes","volume":"53","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021111916153567000_BST-2021-0343CC106","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jconrel.2017.01.025","article-title":"To heat or not to heat: challenges with clinical translation of thermosensitive liposomes","volume":"249","year":"2017","journal-title":"J. Control Release"},{"key":"2021111916153567000_BST-2021-0343CC107","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jconrel.2013.03.036","article-title":"Thermosensitive liposomes for localized delivery and triggered release of chemotherapy","volume":"169","year":"2013","journal-title":"J. Control Release"},{"key":"2021111916153567000_BST-2021-0343CC108","doi-asserted-by":"publisher","first-page":"119266","DOI":"10.1016\/j.ijpharm.2020.119266","article-title":"Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP: a case study using protein-loaded liposomes","volume":"582","year":"2020","journal-title":"Int. J. Pharm."},{"key":"2021111916153567000_BST-2021-0343CC109","doi-asserted-by":"publisher","first-page":"119566","DOI":"10.1016\/j.ijpharm.2020.119566","article-title":"Rapid scale-up and production of active-loaded PEGylated liposomes","volume":"586","year":"2020","journal-title":"Int. J. Pharm."},{"key":"2021111916153567000_BST-2021-0343CC110","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/ncb2024","article-title":"miR-9, a MYC\/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis","volume":"12","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"2021111916153567000_BST-2021-0343CC111","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1039\/b701744h","article-title":"Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems","volume":"31","year":"2007","journal-title":"Chem. Commun."},{"key":"2021111916153567000_BST-2021-0343CC112","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1002\/anie.200250653","article-title":"Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change","volume":"42","year":"2003","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2021111916153567000_BST-2021-0343CC113","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s00216-005-0247-7","article-title":"Nano-oncology: drug delivery, imaging, and sensing","volume":"384","year":"2006","journal-title":"Anal. Bioanal. Chem."},{"key":"2021111916153567000_BST-2021-0343CC114","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1039\/C9TB02246E","article-title":"Stimuli-responsive nanoparticle-assisted immunotherapy: a new weapon against solid tumours","volume":"8","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"2021111916153567000_BST-2021-0343CC115","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.bioactmat.2020.12.010","article-title":"The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment","volume":"6","year":"2021","journal-title":"Bioact Mater"},{"key":"2021111916153567000_BST-2021-0343CC116","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","year":"2011","journal-title":"Cell"},{"key":"2021111916153567000_BST-2021-0343CC117","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","year":"2000","journal-title":"Cell"},{"key":"2021111916153567000_BST-2021-0343CC118","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.biomaterials.2016.06.032","article-title":"Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy","volume":"102","year":"2016","journal-title":"Biomaterials"},{"key":"2021111916153567000_BST-2021-0343CC119","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.biomaterials.2014.10.053","article-title":"CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses","volume":"40","year":"2015","journal-title":"Biomaterials"},{"key":"2021111916153567000_BST-2021-0343CC120","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.phrs.2016.10.016","article-title":"Nanoparticles for cancer gene therapy: recent advances, challenges, and strategies","volume":"114","year":"2016","journal-title":"Pharmacol. Res."},{"key":"2021111916153567000_BST-2021-0343CC121","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.addr.2013.12.008","article-title":"Liposomal siRNA nanocarriers for cancer therapy","volume":"66","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021111916153567000_BST-2021-0343CC122","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/mt.2010.136","article-title":"Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy","volume":"18","year":"2010","journal-title":"Mol. Ther."},{"key":"2021111916153567000_BST-2021-0343CC123","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1158\/0008-5472.CAN-06-4535","article-title":"Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system","volume":"67","year":"2007","journal-title":"Cancer Res."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/49\/5\/2253\/923657\/bst-2021-0343c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/49\/5\/2253\/923657\/bst-2021-0343c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T16:33:34Z","timestamp":1637339614000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/49\/5\/2253\/230020\/Development-of-next-generation-nanomedicine-based"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":123,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10,28]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20210343","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]}}}